vs
Side-by-side financial comparison of DaVita (DVA) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $3.6B, roughly 1.0× DaVita). On growth, DaVita posted the faster year-over-year revenue change (12.3% vs 5.0%). Over the past eight quarters, DaVita's revenue compounded faster (6.6% CAGR vs 0.5%).
DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
DVA vs VTRS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $3.7B |
| Net Profit | $234.2M | — |
| Gross Margin | — | 31.1% |
| Operating Margin | 15.5% | -5.2% |
| Net Margin | 6.5% | — |
| Revenue YoY | 12.3% | 5.0% |
| Net Profit YoY | 43.8% | — |
| EPS (diluted) | $3.22 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.6B | $3.7B | ||
| Q3 25 | $3.4B | $3.7B | ||
| Q2 25 | $3.4B | $3.6B | ||
| Q1 25 | $3.2B | $3.2B | ||
| Q4 24 | $3.3B | $3.5B | ||
| Q3 24 | $3.3B | $3.7B | ||
| Q2 24 | $3.2B | $3.8B |
| Q1 26 | $234.2M | — | ||
| Q4 25 | $234.2M | — | ||
| Q3 25 | $150.3M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $162.9M | — | ||
| Q4 24 | $259.3M | — | ||
| Q3 24 | $214.7M | — | ||
| Q2 24 | $222.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 38.2% |
| Q1 26 | 15.5% | — | ||
| Q4 25 | 15.5% | -5.2% | ||
| Q3 25 | 14.8% | 4.8% | ||
| Q2 25 | 15.9% | 6.5% | ||
| Q1 25 | 13.6% | -88.9% | ||
| Q4 24 | 17.2% | -5.1% | ||
| Q3 24 | 16.4% | 6.0% | ||
| Q2 24 | 15.9% | -6.3% |
| Q1 26 | 6.5% | — | ||
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 7.9% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 7.0% | — |
| Q1 26 | $3.22 | — | ||
| Q4 25 | $3.22 | $-0.34 | ||
| Q3 25 | $2.04 | $-0.11 | ||
| Q2 25 | $2.58 | $0.00 | ||
| Q1 25 | $2.00 | $-2.55 | ||
| Q4 24 | $3.08 | $-0.43 | ||
| Q3 24 | $2.50 | $0.08 | ||
| Q2 24 | $2.50 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $700.7M | $1.3B |
| Total DebtLower is stronger | $10.2B | — |
| Stockholders' EquityBook value | $-651.1M | $14.7B |
| Total Assets | $17.5B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $700.7M | — | ||
| Q4 25 | $700.7M | $1.3B | ||
| Q3 25 | $736.5M | $975.3M | ||
| Q2 25 | $739.4M | $566.4M | ||
| Q1 25 | $511.9M | $755.0M | ||
| Q4 24 | $846.0M | $734.8M | ||
| Q3 24 | $1.1B | $1.9B | ||
| Q2 24 | $437.2M | $917.2M |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $10.2B | — | ||
| Q3 25 | $10.2B | — | ||
| Q2 25 | $10.1B | — | ||
| Q1 25 | $9.6B | — | ||
| Q4 24 | $9.2B | — | ||
| Q3 24 | $9.3B | — | ||
| Q2 24 | $8.5B | — |
| Q1 26 | $-651.1M | — | ||
| Q4 25 | $-651.1M | $14.7B | ||
| Q3 25 | $-571.9M | $15.2B | ||
| Q2 25 | $-369.6M | $15.6B | ||
| Q1 25 | $-267.1M | $15.7B | ||
| Q4 24 | $121.1M | $18.6B | ||
| Q3 24 | $386.7M | $19.8B | ||
| Q2 24 | $632.9M | $19.5B |
| Q1 26 | $17.5B | — | ||
| Q4 25 | $17.5B | $37.2B | ||
| Q3 25 | $17.6B | $37.9B | ||
| Q2 25 | $17.5B | $38.4B | ||
| Q1 25 | $17.1B | $38.5B | ||
| Q4 24 | $17.3B | $41.5B | ||
| Q3 24 | $17.5B | $44.8B | ||
| Q2 24 | $17.0B | $45.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 75.76× | — | ||
| Q3 24 | 23.95× | — | ||
| Q2 24 | 13.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $815.8M |
| Free Cash FlowOCF − Capex | — | $619.3M |
| FCF MarginFCF / Revenue | — | 16.8% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $540.7M | $815.8M | ||
| Q3 25 | $841.5M | $744.9M | ||
| Q2 25 | $324.2M | $219.7M | ||
| Q1 25 | $180.0M | $535.5M | ||
| Q4 24 | $547.6M | $482.7M | ||
| Q3 24 | $810.4M | $826.5M | ||
| Q2 24 | $798.8M | $379.1M |
| Q1 26 | — | — | ||
| Q4 25 | $395.3M | $619.3M | ||
| Q3 25 | $675.4M | $658.1M | ||
| Q2 25 | $203.1M | $166.8M | ||
| Q1 25 | $36.8M | $492.9M | ||
| Q4 24 | $377.0M | $342.3M | ||
| Q3 24 | $671.4M | $749.5M | ||
| Q2 24 | $674.1M | $320.3M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 16.8% | ||
| Q3 25 | 19.7% | 17.6% | ||
| Q2 25 | 6.0% | 4.7% | ||
| Q1 25 | 1.1% | 15.2% | ||
| Q4 24 | 11.4% | 9.7% | ||
| Q3 24 | 20.6% | 20.1% | ||
| Q2 24 | 21.2% | 8.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 5.3% | ||
| Q3 25 | 4.9% | 2.3% | ||
| Q2 25 | 3.6% | 1.5% | ||
| Q1 25 | 4.4% | 1.3% | ||
| Q4 24 | 5.2% | 4.0% | ||
| Q3 24 | 4.3% | 2.1% | ||
| Q2 24 | 3.9% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.31× | — | ||
| Q3 25 | 5.60× | — | ||
| Q2 25 | 1.63× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | 3.77× | — | ||
| Q2 24 | 3.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVA
Segment breakdown not available.
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
